GALECTO13G

Company

Damora Therapeutics, Inc.

Filed

October 3, 2023

Accession Number

0001995601-23-000002

A Schedule 13G is filed when a passive investor acquires more than 5% of a company's shares without intent to influence control. Learn more about SC 13G filings →